


PHARMACEUTICAL 2019

FIVE PRIME THERAPEUTICS INC. Rank 70 of 363







PHARMACEUTICAL 2019



FIVE PRIME THERAPEUTICS INC. Rank 70 of 363

The relative strengths and weaknesses of FIVE PRIME THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of FIVE PRIME THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 53% points. The greatest weakness of FIVE PRIME THERAPEUTICS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 44% points.

The company's Economic Capital Ratio, given in the ranking table, is 209%, being 173% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	288,568
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	27,487
Liabilities, Non-Current	0
Other Assets	4,248
Other Compr. Net Income	370
Other Expenses	0
Other Liabilities	0
Other Net Income	5,708
Other Revenues	49,868
Property and Equipment	28,718
Research and Development	156,352
Selling, General and Administrative Expense	39,671

Output Variable	Value in 1000 USD
Assets	321,534
Liabilities	27,487
Expenses	196,023
Revenues	49,868
Stockholders Equity	294,047
Net Income	-140,447
Comprehensive Net Income	-140,262
Economic Capital Ratio	209%

